Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 7, 2014, Pages 1069-1077

  Kamat, Ashish M ^a   Vlahou, Antonia ^b   Taylor, John A ^c   Hudson, Mdliss A ^d   Pesch, Beate ^e   Ingersoll, Molly A ^f   Todenhöfer, Tilmann ^g   van Rhijn, Bas ^h   Kassouf, Wassim ⁱ   Barton Grossman, H ^a   Behrens, Thomas ^e   Chandra, Ashish ^j   Goebell, Peter J ^k   Palou, Juan ^l   Sanchez Carbayo, Marta ^m   Schmitz Dräger, Bernd J ⁿ  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Academy of Athens Biomedical Research Foundation   (Greece)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d OCHSNER CLINIC FOUNDATION   (United States)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f INSTITUT PASTEUR   (France)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

ⁱ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^j ST THOMAS HOSPITAL   (United Kingdom)

^k UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^l FUNDACIÓ PUIGVERT   (Spain)

^m CIC BIOGUNE   (Spain)

ⁿ Urologie 24 Urologie Schön Klinik Nürnberg Fürth   (Germany)

more..

Author keywords

Diagnosis; Disease management; High grade; Non muscle invasive bladder cancer; Urine markers

Indexed keywords

CYCLIN D1; METALLOTHIONEIN; MOLECULAR MARKER; NUCLEAR MATRIX PROTEIN 22; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TUMOR MARKER;

CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CLINICAL DECISION MAKING; CYTOLOGY; DIAGNOSTIC VALUE; FLUORESCENCE IN SITU HYBRIDIZATION; HIGH RISK PATIENT; HUMAN; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; URINALYSIS; BLADDER TUMOR; URINE;

HUMANS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84925402576     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.06.017     Document Type: Review

References (42)

1. van Rhijn BWG, Catto JW, Goebell PJ, Knüchel R, Shariat SF, Sanchez-Carbayo M, et al. Molecular markers for urothelial bladder cancer prognosis: towards implementation in clinical practice. Urol Oncol [this issue].
2. Schmitz-Dräger B.J., Todenhöfer T., van Rhijn B., Pesch B., Hudson M.A., Chandra A., et al. Considerations on the use of urine markers in the management of patients with low/intermediate risk non muscle-invasive bladder cancer. Urol Oncol 2014, [pii:S1078-1439(13)00450-X].
3. Lotan Y., Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003, 61:109-118. [discussion 118].
4. van Rhijn B.W.G., van der Poel H.G., van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005, 47:736-748.
5. Mowatt G., Zhu S., Kilonzo M., et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010, 14:1-331. [iii-iv].
6. Schmitz-Dräger BJ, Droller M, Lotan Y, Lokeshwar VB, van Rhijn B, Hemstreet GP, et al. Molecular markers for bladder cancer screening, early diagnosis and surveillance. In: Soloway M, Khoury S. editors Bladder cancer: 2nd international consultation on bladder tumors, vol 21. Paris, France: Editions; 2012. p. 171-205.
7. Goebell P.J., Groshen S., Schmitz-Dräger B.J. p53 immunohistochemistry in bladder cancer-a new approach to an old question. Urol Oncol 2010, 28:377-388. for the INTERNATIONAL STUDY-INITIATIVE ON BLADDER CANCER (ISBC).
8. Shariat SF, Droller M, Fradet Y, Hemstreet G, Hudson MA, Karakiewicz P, et al. Molecular markers for bladder cancer staging and prognosis. In: Soloway M, Khoury S. editors Bladder cancer: 2nd international consultation on bladder tumors. vol 21. Paris, France: Editions; 2012. p. 207-229.
9. Kamat A.M., Hegarty P.K., Gee J.R., Clark P.E., Svatek R.S., Hegarty N., et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 2013, 63:4-15.
10. Kamat A.M., Dickstein R.J., Messetti F., Anderson R., Pretzsch S.M., Gonzalez G.N., et al. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial. J Urol 2012, 187:862-867.
11. Zuiverloon T.C., Nieuweboer A.J., Vékony H., Kirkels W.J., Bangma C.H., Zwarthoff E.C. Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 2012, 61:128-145.
12. Babjuk M, Burger M, Zigeuner R, Shariat S, van Rhijn B, Compérat E, et al. Guidelines on non-muscle invasive bladder cancer Ta, T1 and CIS. European Association of Urology; 2013. Available at: http://www.uroweb.org/gls/pdf/05_TaT1_Bladder_Cancer_LR.pdf.
13. Sylvester R.J., van der Meijden A.P., Oosterlinck W., Witjes J.A., Bouffioux C., Denis L., et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-475.
14. Epstein J.I., Amin M.B., Reuter V.R., et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998, 22:1435-1448.
15. Sauter G., Algaba F., Amin M., et al. Tumours of the urinary system: non-invasive urothelial neoplasias. WHO classification of classification of tumours of the urinary system and male genital organs 2004, 29-34. IARCC Press, Lyon. J.N. Eble, G. Sauter, E. Jl, I. Sesterhenn (Eds.).
16. van der Aa M.N., Steyerberg E.W., Bangma C., van Rhijn B.W., Zwarthoff E.C., van der Kwast T.H. Cystoscopy revisited as the gold standard for detection of bladder cancer recurrences: diagnostic review bias in a randomised prospective trial (Cefub-Trial). J Urol 2010, 183:76-80.
17. Yafi F.A., Brimo F., Auger M., Aprikian A., Tanguay S., Kassouf W. Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer. Urol Oncol 2013, [pii:S1078-1439(12)00343-2].
18. Schmitz-Dräger B.J., Tirsar L.-A., Schmitz-Dräger C., Dörsam J., Mellan Z., Bismarck E., et al. Immunocytology in the assessment of patients with asymptomatic hematuria. World J Urol 2008, 26:31-37.
19. Messer J., Shariat S.F., Brien J.C., Herman M.P., Ng C.K., Scherr D.S., et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 2011, 108:701-705.
20. Todenhöfer T., Hennenlotter J., Esser M., Aufderklamm S., Mohrhardt S., Gakis G., et al. Stepwise applications of immunocytology and fish in the surveillance of patients with non-muscle invasive bladder cancer. J Urol 2013, 189S:e526.
21. Burger M., Grossman H.B., Droller M., Schmidbauer J., Hermann G., Drăgoescu O., et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 2013, 64:846-854.
22. Goebell PJ, Kamat AM, Sylvester R, Black P, Droller M, Godoy G, et al. Assessing the quality of studies on the diagnostic accuracy of tumor markers. Urol Oncol [this issue].
23. Boman H., Hedelin H., Holmäng S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002, 167:80-83.
24. Sánchez-Carbayo M., Herrero E., Megías J., Mira A., Soria F. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol 1999, 162:1951-1956.
25. Raitanen M.P. The role of BTA stat test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol 2008, 26:45-50. FinnBladder Group.
26. van Rhijn B.W. Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer. Urol Oncol 2012, 30:518-523.
27. Shariat S.F., Savage C., Chromecki T.F., Sun M., Scherr D.S., Lee R.K., et al. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. Cancer 2011, 117:2892-2897.
28. Barbieri C.E., Cha E.K., Chromecki T.F., Dunning A., Lotan Y., Svatek R.S., et al. Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. BJU Int 2012, 109:685-690.
29. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008, 26:646-651.
30. van der Aa M.N., Zwarthoff E.C., Steyerberg E.W., Boogaard M.W., Nijsen Y., van der Keur K.A., et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB]). Eur Urol 2009, 55:659-668.
31. Todenhöfer T., Hennenlotter J., Esser M., Mohrhardt S., Tews V., Aufderklamm S., et al. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma. Cancer Cytopathol 2013, 121:252-260.
32. Pesch B., Brüning T., Johnen G., Casjens S., Bonberg N., Taeger D., et al. Biomarker research with prospective study designs for the early detection of cancer. Biochim Biophys Acta 2014, 1844(5):874-883.
33. Yoder B.J., Skacel M., Hedgepeth R., Babineau D., Ulchaker J.C., Liou L.S., et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007, 127:295-301.
34. Gofrit O.N., Zorn K.C., Silvestre J., Shalhav A.L., Zagaja G.P., Msezane L.P., et al. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer. Urol Oncol 2008, 26:246-249.
35. Skacel M., Fahmy M., Brainard J.A., Pettay J.D., Biscotti C.V., Liou L.S., et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003, 169:2101-2105.
36. Lotan Y., Bensalah K., Ruddell T., Shariat S.F., Sagalowsky A.I., Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2008, 179:2164-2169.
37. van Rhijn B.W., van der Kwast T.H., Liu L., Fleshner N.E., Bostrom P.J., Vis A.N., et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol 2012, 187:310-314.
38. Alkhateeb S.S., Neill M., Bar-Moshe S., Rhijn B.V., Kakiashvili D.M., Fleshner N., et al. Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. Urol Ann 2011, 3:119-126.
39. Todenhöfer T., Hennenlotter J., Aufderklamm S., Kühs U., Gakis G., Germann M., et al. Individual risk assessment in bladder cancer patients based on a multi-marker panel. J Cancer Res Clin Oncol 2013, 139:49-56.
40. Fernández M.I., Parikh S., Grossman H.B., Katz R., Matin S.F., Dinney C.P., et al. The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urol Oncol 2012, 30:821-824.
41. Wallace D.M., Bryan R.T., Dunn J.A., Begum G., Bathers S. Delay and survival in bladder cancer. BJU Int 2002, 89:868-878. West Midlands Urological Research Group.
42. Hollenbeck B.K., Dunn R.L., Ye Z., Hollingsworth J.M., Skolarus T.A., Kim S.P., et al. Delays in diagnosis and bladder cancer mortality. Cancer 2010, 116:5235-5242.